Skip to main contentSkip to navigation
Sirius Investors
IGM Biosciences, Inc.

IGM Biosciences, Inc.

IGMS
NASDAQHealthcare

IGM Biosciences, Inc. (IGMS) Investment Research Dashboard

About IGM Biosciences, Inc. (IGMS) stock analysis

Get live IGMS stock price $1.27, comprehensive IGM Biosciences, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time IGMS stock data and investment insights.

1.27
0.00%Today
Market Cap
77.50M
Volume
1.59M
52W High
22.50
52W Low
0.92

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

IGM Biosciences, Inc. operates as a biotechnology firm dedicated to advancing Immunoglobulin M (IgM) antibodies. These novel therapeutic agents are being developed for a broad spectrum of conditions, including various cancers, infectious ailments, an...

Company Information

CEO
Mary Beth Harler
Sector
Healthcare
Industry
Biotechnology
Employees
149

Contact Information

Address
325 East Middlefield Road
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.59) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for IGM Biosciences, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for IGM Biosciences, Inc.
  • Investors should consider how IGM Biosciences, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

77.50M

P/E Ratio (TTM)

-1.41

Beta

0.59

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

76/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Communication Services+1.4%+2.9%+4.3%22.2
88/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
76/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.7%+1.2%29.7
61/100⭐⭐⭐⭐
Basic Materials+0.4%+1.1%-0.2%25.2
58/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.5%29.2
41/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
35/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
21/100
Consumer Cyclical+0.5%-0.9%-5.6%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.